BiotechTube

Dotinurad + Febuxostat

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gout

Conditions

Gout

Trial Timeline

Dec 21, 2021 → Jun 14, 2023

NCT ID
NCT05007392

About Dotinurad + Febuxostat

Dotinurad + Febuxostat is a phase 3 stage product being developed by Eisai for Gout. The current trial status is completed. This product is registered under clinical trial identifier NCT05007392. Target conditions include Gout.

What happened to similar drugs?

7 of 20 similar drugs in Gout were approved

Approved (7) Terminated (3) Active (11)
🔄febuxostat + AllopurinolAstellas PharmaPhase 3
🔄SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
🔄SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
🔄Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
❌Canakinumab, ACZ885 + Triamcinolone acetonideNovartisPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05007392Phase 3Completed

Competing Products

20 competing products in Gout

See all competitors
ProductCompanyStageHype Score
febuxostat + AllopurinolAstellas PharmaPhase 3
40
BaricitinibEli LillyPhase 2
35
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 1
25
SHR4640 tablet + SHR4640 tablet + febuxostat tablet + SHR4640 placebo tabletJiangsu Hengrui MedicinePhase 2
31
repaglinide; midazolam; SHR4640 + repaglinide; midazolam; SHR4640; SHR4640 placebo + repaglinide; midazolam; SHR4640 placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 + placeboJiangsu Hengrui MedicinePhase 1
29
SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
40
Colchicine + Febuxostat + SHR4640Jiangsu Hengrui MedicinePhase 1
29
SHR4640 + AllopurinolJiangsu Hengrui MedicinePhase 3
40
SHR4640 ；Febuxostat + SHR4640 ; Febuxostat + SHR4640 + SHR4640 + FebuxostatJiangsu Hengrui MedicinePhase 2
42
SHR4640Jiangsu Hengrui MedicinePhase 1
25
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
47
HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
40
SHR4640 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Zurampic® + Control group: xanthine oxidase inhibitor monotherapyAstraZenecaPre-clinical
18
Risk of selected safety eventsAstraZenecaPre-clinical
26
AZD6140 + Placebo to match AZD6140AstraZenecaPhase 1
29
RDEA3170 + Allopurinol + PlaceboAstraZenecaPhase 2
35
RDEA3170 + Febuxostat + BenzbromaroneAstraZenecaPhase 1/2
32
Canakinumab pre-filled syringe + Canakinumab lyophilized powder + Triamcinolone Acetonide + PlaceboNovartisPhase 3
40